Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections

被引:1194
作者
Surawicz, Christina M. [1 ]
Brandt, Lawrence J. [2 ,3 ]
Binion, David G. [4 ]
Ananthakrishnan, Ashwin N. [5 ,6 ]
Curry, Scott R. [7 ]
Gilligan, Peter H. [8 ]
McFarland, Lynne V. [9 ,10 ]
Mellow, Mark [11 ]
Zuckerbraun, Brian S. [12 ,13 ]
机构
[1] Univ Washington, Sch Med, Dept Med, Div Gastroenterol, Seattle, WA 98104 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Montefiore Med Ctr, Div Gastroenterol, Bronx, NY 10467 USA
[4] Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA
[5] Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
[7] Univ Pittsburgh, Dept Med, Div Infect Dis, Pittsburgh, PA USA
[8] Univ North Carolina Hosp, Clin Microbiol Immunol Labs, Chapel Hill, NC USA
[9] VA Puget Sound Hlth Care Syst, Dept Vet Affairs, Seattle, WA USA
[10] Univ Washington, Sch Publ Hlth, Dept Med Chem, Seattle, WA 98104 USA
[11] INTEGRIS Baptist Med Ctr, Digest Hlth Ctr, Oklahoma City, OK USA
[12] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA
[13] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA
关键词
INFLAMMATORY-BOWEL-DISEASE; POLYMERASE-CHAIN-REACTION; HEALTH-CARE EPIDEMIOLOGY; SERUM ANTIBODY-RESPONSE; PUMP INHIBITOR THERAPY; REAL-TIME PCR; TOXIN-A; RISK-FACTORS; FECAL MICROBIOTA; DOUBLE-BLIND;
D O I
10.1038/ajg.2013.4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.
引用
收藏
页码:478 / 498
页数:21
相关论文
共 251 条
[1]   Recurrent Clostridium difficile colitis:: Case series involving 18 patients treated with donor stool administered via a nasogastric tube [J].
Aas, J ;
Gessert, CE ;
Bakken, JS .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :580-585
[2]   Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A [J].
Aboudola, S ;
Kotloff, KL ;
Kyne, L ;
Warny, M ;
Kelly, EC ;
Sougioultzis, S ;
Giannasca, PJ ;
Monath, TP ;
Kelly, CP .
INFECTION AND IMMUNITY, 2003, 71 (03) :1608-1610
[3]   Intravenous Immunoglobulin for the Treatment of Clostridium difficile Infection: A Review [J].
Abougergi, Marwan S. ;
Kwon, John H. .
DIGESTIVE DISEASES AND SCIENCES, 2011, 56 (01) :19-26
[4]  
Al-Eidan FA, 2000, J CLIN PHARM THER, V25, P101
[5]   Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Li, Yuejin ;
Pultz, Michael J. ;
Riggs, Michelle M. ;
Donskey, Curtis J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) :2403-2406
[6]   Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin [J].
Al-Nassir, Wafa N. ;
Sethi, Ajay K. ;
Nerandzic, Michelle M. ;
Bobulsky, Greg S. ;
Jump, Robin L. P. ;
Donskey, Curtis J. .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :56-62
[7]   Early and late onset Clostridium difficile-associated colitis following liver transplantation [J].
Albright, Jeffrey B. ;
Bonatti, Hugo ;
Mendez, Julio ;
Kramer, David ;
Stauffer, John ;
Hinder, Ronald ;
Michel, Jaime A. ;
Dickson, Rolland C. ;
Hughes, Chris ;
Nguyen, Justin ;
Chua, Heidi ;
Hellinger, Walter .
TRANSPLANT INTERNATIONAL, 2007, 20 (10) :856-866
[8]   Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea [J].
Alfa, MJ ;
Kabani, A ;
Lyerly, D ;
Moncrief, S ;
Neville, LM ;
Al-Barrak, A ;
Harding, GKH ;
Dyck, B ;
Olekson, K ;
Embil, JM .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (07) :2706-2714
[9]  
Ali SO, 2008, AM SURGEON, V74, P20
[10]   Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guerin [J].
Alkhateeb, Sultan S. ;
Neill, Mischel ;
Bar-Moshe, Sas ;
Van Rhijn, Bas ;
Kakiashvili, David M. ;
Fleshner, Neil ;
Jewett, Michael ;
Petein, Michel ;
Schulman, Claude ;
Hanna, Sally ;
Bostrom, Peter J. ;
Roumeguere, Thierry ;
Shariat, Shahrokh F. ;
Rorive, Sandrine ;
Zlotta, Alexandre R. .
UROLOGY ANNALS, 2011, 3 (03) :119-126